CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

The purpose of this study is to evaluate the safety and feasibility of a treatment holiday strategy directed by CD70-targeted immuno-PET/CT in patients with metastatic clear cell renal cell carcinoma (mccRCC). Specifically, the study aims to assess whether patients who achieve both anatomical disease control and metabolic response after 12 months of first-line PD-1/PD-L1 ICI + VEGFR-TKI combination therapy can safely pause their treatment, improve quality of life without compromising therapeutic efficacy.

NCT Number	NCT07615348
Lead Sponsor	Jinling Hospital, China
Conditions	Metastatic Clear Cell Renal Cell Carcinoma
Enrollment	75 participants
Start Date	2026-06-16
Primary Completion	2028-08-10 (estimated)
Study Completion	2029-08-10 (estimated)
Updated on ClinicalTrials.gov	2026-08-11